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Abstract
Biology-based markers to confirm or aid in the diagnosis or prognosis of chronic GVHD after 
allogeneic hematopoietic cell transplantation (HCT) or monitor its progression are critically 
needed to facilitate evaluation of new therapies. Biomarkers have been defined as any 
characteristic that is objectively measured and evaluated as an indicator of a normal biological or 
pathogenic process, a pharmacologic response to a therapeutic intervention. Applications of 
biomarkers in chronic GVHD clinical trials or patient management include: a) diagnosis and 
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assessment of chronic GVHD disease activity, including distinguishing irreversible damage from 
continued disease activity, b) prognostic risk to develop chronic GVHD, and c) prediction of 
response to therapy. Sample collection for chronic GVHD biomarkers studies should be well-
documented following established quality control guidelines for sample acquisition, processing, 
preservation and testing, at intervals that are both calendar- and event-driven. The consistent 
therapeutic treatment of subjects and standardized documentation needed to support biomarker 
studies are most likely to be provided in prospective clinical trials. To date, no chronic GVHD 
biomarkers have been qualified for utilization in clinical applications. Since our previous chronic 
GVHD Biomarkers Working Group report in 2005, an increasing number of chronic GVHD 
candidate biomarkers are available for further investigation. This paper provides a four-part 
framework for biomarker investigations: identification, verification, qualification, and application 
with terminology based on Food and Drug Administration and European Medicines Agency 
guidelines.
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BACKGROUND
Chronic GVHD is one of the most important long-term complications of allogeneic blood 
and marrow transplantation, resulting in significant morbidity and mortality [1]. Unlike 
acute GVHD, chronic GVHD is insidious in its onset and the diagnosis can be difficult. 
Moreover, chronic GVHD is a multifaceted disease that can affect almost all organs and 
tissues in the body. Thus, the identification and verification of biomarkers for chronic 
GVHD is more difficult than for acute GVHD. The scoring system proposed by the NIH 
Consensus Development Project on Criteria for Clinical Trials in chronic GVHD [2] has 
now been widely adopted by HCT centers. However, clinical characteristics are not fully 
informative in predicting the severity of the disease, response to therapy, or survival, and are 
not adequate to distinguish disease activity from irreversible tissue damage during treatment 
[3]. As an adjunct to clinical and histological criteria, the availability of biomarkers for 
chronic GVHD could potentially improve the classification of patients into risk groups and 
thereby refine chronic GVHD diagnosis, estimate the risk of developing chronic GVHD or 
predict response to therapy.
The pathogenesis of chronic GVHD involves a number of biological mechanisms potentially 
contributing to its development and evolution. Historically, chronic GVHD was believed to 
be a chronic continuation of the same effector mechanisms that cause acute GVHD, i.e., 
donor T cells having specificity for recipient-restricted histocompatibility antigens that 
produce cytokines. However, differences in the clinical presentations of acute and chronic 
GVHD suggest that the effector mechanisms might differ. Further, therapies that are 
clinically effective in treating acute GVHD are much less effective for chronic GVHD. 
Together, this suggests that both unique biomarkers and pathophysiologic mechanisms may 
be involved in chronic GVHD.
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Candidate biomarkers may be identified from their correlations with certain chronic GVHD 
phenotypes. While some correlations might not reflect the underlying pathology, others will 
suggest new pathophysiologic pathways and potential therapeutic targets. Alternatively, 
potential biomarkers may be identified via biological hypotheses generated from pre-clinical 
or theoretical models of chronic GVHD pathophysiology. However, a biomarker does not 
necessarily directly represent an effector mechanism of chronic GVHD but may reflect a 
counter-response to control GVHD, or result from nonspecific inflammation or damage.
Purpose of this document
The purpose of this document is to facilitate the identification, verification, qualification and 
application of chronic GVHD biomarkers. In this document we discuss: a) a standardized 
nomenclature for biomarkers usage, b) a core set of potentially confounding factors that 
must be considered when measuring different types of chronic GVHD biomarkers, c) critical 
concepts and a recommended decision process specific to the selection and development of 
biomarkers in chronic GVHD, and d) considerations for a repository with the minimal 
essential clinical data to be provided with each sample.
Summary of 2014 changes
This document replaces the 2005 report [4] of the Biomarker Working Group of the NIH 
Consensus Development Project on Criteria for Clinical Trials in chronic GVHD.
SUMMARY OF RECOMMENDATIONS
The Biomarker Working Group makes the following recommendations:
1. Biomarker(s) of chronic GVHD should include all of the following components 
whenever possible:
a. Marker should be identified as diagnostic, prognostic, or predictive of the 
potential to respond to a treatment, or correlate with response to a treatment 
that will lead to an important clinical outcome (see Table 1).
b. Use of rigorous methodology for measuring the biomarker.
c. Confirmation in at least 2 independent cohorts, each having sufficient power 
for statistical significance for a clinically relevant hypothesis.
This rigor is required because the observation of a significant association in 
a single data set does not ensure that the findings can be generalized to other 
data sets or that the association is specific for the investigated condition. A 
biomarker confirmed to have a strong association with the investigated 
condition in at least two independent cohorts would support its use in 
chronic GVHD clinical trials or patient management. To identify such 
biomarkers, a coordinated approach to the identification, verification, 
qualification, and application of biomarkers should be implemented. Prior to 
clinical application, a higher degree of confidence may be required, such as 
confirmation of results by an independent group in a different environment 
and clinical setting.
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2. Both hypothesis-driven studies and discovery-based approaches for identification 
of chronic GVHD biomarkers are likely to be successful in different circumstances.
3. Ideally, both chronic GVHD observational prospective studies and chronic GVHD 
clinical therapeutic trials should include correlative biological studies to allow the 
identification, verification, qualification and application of biomarkers whenever 
possible. The main advantages of observational prospective studies are: (1) the 
study population can be more heterogeneous and representative of the entire 
population; (2) generally longer longitudinal follow-up than clinical trials; and (3) 
more patients can be studied. Clinical trials have the advantages that: (1) the study 
population is often more homogeneous; (2) treatment is controlled; (3) clear 
outcome assessment; and (4) if randomized, potential sources of bias are 
minimized.
4. Samples from well-documented cases and controls should be stored using 
standardized protocols as proposed in this consensus paper, in order to create a 
resource for future biomarker studies. Samples types to be collected on cases and 
controls and minimal essential clinical data to be provided with each sample are 
detailed below.
DEFINITIONS OF BIOMARKERS AND THEIR APPLICATIONS
A biomarker has been defined by the NIH Biomarker Working Group as a characteristic that 
is objectively measured as an indicator of normal biological or pathogenic processes, or 
biological and clinical responses to a therapeutic intervention [5]. The Institute of Medicine 
has further defined “objectively” to mean “reliably and accurately” [6]. The term 
“biomarker” commonly refers to a biochemical variable (circulating protein or other 
biomolecule). Therefore, for the purposes of this document, certain evaluations that are 
routinely performed to determine the diagnosis of chronic GVHD or to assess the clinical 
severity of the disease are not discussed but may be considered as biomarkers in certain 
circumstances. Examples of such evaluations include pulmonary function testing, liver 
function testing, and radiographic assessment including computed tomography scans.
Biomarkers can be separated into distinct categories of diagnostic, prognostic, and predictive 
(including response biomarkers), as described in Table 1. Applications of chronic GVHD 
biomarkers critical to clinical care and research studies are summarized below and in Table 
1. The definitions have been updated to reflect usage by the FDA and EMA [7, 8].
1. Diagnose chronic GVHD. For example, a biomarker could be used together with 
clinical criteria to determine eligibility for a clinical trial or clarify differential 
diagnosis (e.g., infection, drug reaction, other inflammatory disease vs. chronic 
GVHD). Distinguish cumulative damage or irreversible tissue damage from 
current chronic GVHD activity. Many of the organ systems involved in chronic 
GVHD develop cumulative tissue damage, and grading scales do not distinguish 
well between the extent of current areas of inflammatory activity (e.g., infiltrates of 
lymphocytes into tissue) and cumulative damage (sclerotic scarring, loss of 
lacrimal or salivary function due to loss of secretory acini). Identify candidates for 
pre-emptive therapy. For example, anti-HY titers increase weeks to months before 
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clinical manifestations and may identify candidates for pre-emptive therapy or 
suggest the type of treatment that should be used.
2. Prognostic risk to develop chronic GVHD. For example, gene polymorphisms in 
either the donor or recipient may be associated with risk of development of chronic 
GVHD. Identifying prognostic markers for development of severe forms of chronic 
GVHD, before onset or at the time of initial diagnosis chronic GVHD, is of 
particular interest. For example, a biomarker that could estimate the risk of severe 
GVHD leading to serious sequelae would be useful to help guide decisions about 
the need for and intensity of treatment.
3. Predict potential for response to therapy. For example, a biomarker may 
distinguish between different pathophysiologic processes that cause chronic GVHD 
and aid in determining treatments that are most likely to provide benefit for an 
individual patient.
4. Serve as an intermediate marker of response to treatment, particularly a response 
related to a long-term outcome such as nonrelapse mortality. For example, a 
biomarker could be used to monitor therapeutic response. This type of biomarker 
could also help guide decisions about treatment management by revealing that a 
treatment has not resulted in an adequate response and that a change in treatment is 
warranted.
Biomarkers that could be used to predict response to treatment, measure disease activity or 
distinguish reversible disease activity from irreversible damage would have very high 
clinical utility, since currently available clinical tools are not adequate for these purposes. In 
addition, biomarkers that are prognostic for the risk of developing severe chronic GVHD 
would also have high utility and could be used in pre-emptive trials.
Predictive biomarker studies will have to be annotated not only with demographic and 
GVHD-related data available at the time of collection, but also with GVHD data relevant to 
future outcomes. Ideally, samples stored in biorepositories will have outcome data as well, 
but many times are not set up this way. The CIBMTR TED forms have a lower level of 
detail regarding chronic GVHD than may be required for some predictive biomarker 
evaluations. If possible, samples should be de-identified to the repository, and the donating 
center should retain the identification links. When biomarker studies are performed, 
investigators could then contact the centers that donated the sample in order to update the 
data.
RISK FACTORS AND COVARIATES TO CONSIDER
While a biomarker may provide valuable assessment of chronic GVHD, other contributing, 
confounding conditions must also be considered. Some potential confounding factors are 
defined below and summarized in Table 2.
Factors affecting biomarkers directly and independent of onset of chronic GVHD
The conditions of a) immune reconstitution, b) concomitant acute GVHD, c) the type and 
intensity of current immunosuppressive therapy, d) presence of infections, and e) sample 
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processing and storage, may all affect expression of a chronic GVHD biomarker or its 
measurement and interpretation. In particular, the analysis of immune-related biomarker 
data must also account for time from transplant, since immune reconstitution occurs 
gradually. Organ involvement by chronic GVHD (types of tissues involved and NIH score) 
and the clinical presentation at onset reflect the chronic GVHD diagnostic phenotype, which 
may directly affect biomarker levels. Because of the heterogeneity and varied frequency of 
the clinical syndromes of chronic GVHD, it is unlikely that any given biomarkers will be 
applicable to all forms or presentations of this disorder.
Covariates and potential confounding factors
A variety of confounding factors may limit the ability to interpret results of chronic GVHD 
biomarker studies. Each of the following confounding factors may limit the scope and 
application of a particular biomarker or at least must be controlled for as possible 
confounding factors in any analysis: a) recipient characteristics such as age; b) donor 
characteristics including treatment of the donor with G-CSF or other agent (e.g., plerixafor) 
and graft manipulation (e.g., an HLA-haploidentical graft with T cell depletion or with 
administration of cyclophosphamide after transplantation); c) donor source (related versus 
unrelated) and the type of graft (peripheral blood, bone marrow, or umbilical cord blood); 
and d) recipient preparative conditioning regimen.
Donor versus Recipient Chimerism Criteria for evaluation of chronic GVHD Biomarkers
Significant recipient chimerism is associated with a higher frequency of donor tolerance [9, 
10] and could affect the interpretation of chronic GVHD biomarkers when donor-derived 
hematopoiesis is not fully engrafted. In patients with questionable engraftment, chimerism 
should be examined, and the patient should be excluded from biomarker studies if results 
show < 90% donor chimerism, ideally in either lymphoid or myeloid populations.
CRITICAL FRAMEWORK FOR BIOMARKER STUDIES IN CHRONIC GVHD
So far, most potential chronic GVHD biomarkers have been identified based on evaluation 
at a single center or single laboratory, and have not been through all the steps of verification 
and qualification necessary to be approved for use in clinical trials, as discussed below and 
shown in Figure 1. Only a few studies have included patients derived from multiple centers 
or independent cohorts of patients. Thus, we propose a four-part framework for the 
development of chronic GVHD biomarkers (Figure 1). These recommendations are based on 
guidance for biomarker development from the Institute of Medicine [6] and the US Food 
and Drug Administration (FDA) in the Center for Drug Evaluation and Research (CDER) 
[11]. The HCT community will be able to move forward and translate biomarkers into the 
clinic only if these recommendations are carefully applied in order to avoid previous 
mistakes, such as 1) strong reliance on convenience samples rather than a prospectively 
defined population from which specimens are to be collected, 2) absence of a verification 
cohort that is independent of the discovery cohort, 3) improper statistical methods, for 
example, when deriving a multiple factor risk score, and 4) failure to consider commonly 
available clinical information before deducing the additive value of biomarkers. Avoidance 
of these mistakes will allow our HCT community to move forward in translating biomarkers 
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into the clinic [12, 13]. We have used the new recommended terminology in the headers 
below [5, 6] to avoid the term “validation”, whose different meanings have led to confusion. 
In Figure 1 we propose a workflow for biomarker discovery. Each step is explained below.
Step 1: Identification
The initial step is the identification of candidate biomarkers in a small experiment of well-
matched cases and controls selected from the populations in which the biomarker is intended 
for use. At this initial step, it is important to define the clinical context of use and the 
clinician reported outcome (CRO) or patient reported outcome (PRO) data that will be 
captured to assess a clinical endpoint, for example, nonrelapse mortality (NRM) or relapse 
mortality (RM) or more chronic GVHD-specific scales such as the NIH chronic GVHD 0–3 
organ score and the Lee chronic GVHD symptom scale. The most appropriate controls for 
the cases should be defined at this point. It should not be assumed that the same controls are 
appropriate for different clinical contexts. Factors that should be considered in the choice of 
controls are discussed in Table 2.
Step 2: Verification
This step confirms the analytical validity of a test. This includes, among other aspects, the 
test’s reproducibility and accuracy (% coefficient of variation, precision). Test practicality 
should also be considered: is the potential sample to be measured easy to obtain, is the 
sample stable until the test can be performed, and is it cost-effective? Of note, before the 
qualification step, parameters such as cutoff values and sample collection procedures are 
locked down (finalized) and cannot be changed without re-verification of the test under the 
revised conditions.
Step 3: Qualification
This step assesses the robustness of the test in all samples from the intended use population 
for a certain clinical outcome/CRO or PRO (i.e. correctness). Statistical considerations for 
this step are shown in Table 3. Other statistical analyses that have been proposed to estimate 
the performance of biomarkers are reviewed by Pepe et al. [14]. The qualification cohort for 
step 3 should be entirely distinct and separate from the identification cohort previously 
studied in step 1, including different center(s) and different demographics, so long as they 
are consistent with the intended use population. If, however, the demographics are too 
different from the population for which the biomarker’s use is intended, qualification testing 
could fail inappropriately.
Step 4: Application
In this final step, the biomarker is used in the clinic (e.g. to test all patients suspected of 
having chronic GVHD) or in a prospective randomized clinical trial, to test the potential to 
foretell the outcome. If the biomarker successfully qualified, the application step may test: 
(i) practicality of use in a consortium study, (ii) replacement of a clinical scoring system or 
invasive biopsies by a simple blood test, (iii) usefulness as an early surrogate indicator of 
response when testing a new drug as compared to the standard of care. Application testing 
may require Institutional Review Board (IRB) approval as well as Investigational Device 
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Exemption (IDE) or Investigational New Drug (IND) approval, if clinical management of 
patients in the study is based on the outcome of the test.
ENSURING ADEQUATE PATIENT CONSENT FOR CHRONIC GVHD 
BIOMARKER STUDIES
To allow chronic GVHD biomarkers studies, consenting at the time of sample collection is 
essential. Obtaining consent for both current and future research studies can be 
accomplished most easily by the appropriate provision at the time of enrollment, in advance 
of any sample collection followed by de-identifying the sample and providing the correlative 
clinical data. To obtain consent that allows for a broad variety of clinical studies and sharing 
with other investigators, a graded level of consent may need to be obtained in the initial 
consenting process, clarifying whether the participant will allow a) studies on the sample as 
per the currently outlined studies, b) storage for future studies in chronic GVHD, and c) 
storage for future studies that may involve disorders other than chronic GVHD. Due to 
societal sensitivities around “genetic testing” and the common requirement for deposition of 
genetic information into public databases, specialized consent should be obtained for gene-
based studies. The consent process should strive to allow for testing or research exchange of 
coded samples, a process that protects the identity of the subjects but allows access to 
necessary clinical data through the original provider. A model consent form is attached in 
supplementary material.
SAMPLE REPOSITORY FOR INVESTIGATION OF CHRONIC GVHD 
BIOMARKERS
The largest barrier to new chronic GVHD biomarker development is the lack of good quality 
biological samples linked to detailed clinical data. Well-conducted large multicenter 
observation or interventional clinical trials represent excellent formats to provide the 
consistency of standardized documentation needed to support qualification studies 
correlating biomarkers with clinical endpoints of interest. However, single institution or 
observational studies with limited institutional participation in which standardized 
diagnostic criteria are employed may be sufficient for initial identification studies.
These sample repositories not only would support the exchange of chronic GVHD patient 
materials for verification of currently proposed biomarkers, but also provide a resource for 
biomarker discovery through implementation of new technologies. Multiple new 
technologies are becoming available for analysis of biological fluids, including serum, 
plasma, saliva, bronchoalveolar lavage fluid and urine). The proteome and metabolome [15, 
16] can be analyzed by multiplex ELISA [17], and peptide arrays to identify autoantibody 
epitopes [18]. Preserving leukocytes supports future characterization of populations with 
flow cytometric analyses using as many as 20 fluorochrome channels or 40 channels with 
mass cytometry (CyTOF) [19]. Preserving cells also supports cell type-specific sorting for 
molecular analyses. Multiparameter cell characterization can also be done with paraffin 
embedded pathology specimens by fluorescent immunohistochemistry with imaging through 
confocal microscopes and multispectral fluorescent imaging analysis supported by 
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quantitative analysis software [20]. RNA and DNA can be recovered from preserved 
leukocytes, snap-frozen tissue biopsies, from paraffin sections, or even from specific tissue 
areas in sections through laser capture microdissection [21]. Analyses of RNA and miRNA 
transcriptomes have been used to characterize gene expression patterns in autoimmunity and 
inflammation [22, 23]. New bead arrays permit mapping of epigenetic DNA 
hypomethylation to specific gene loci [24]. Verification of identified genes individually by 
quantitative RT-PCR is being replaced by platforms utilizing direct multiplexed 
measurement with RNA and miRNA probe sets, incorporating hundreds of genes to identify 
multigene patterns [25]. High throughput exome sequencing can identify relevant gene 
polymorphisms in donors and recipients more rapidly and at lower cost than whole genome 
approaches, while RNAseq can identify both expression and altered sequences in expressed 
transcripts in sorted, well-defined cell subsets. Key to the integration of data from these 
methodologies is the rapidly maturing development of powerful tools for analysis and 
interpretation of results.
When future biomarker studies are designed, we propose the following considerations. The 
proposed collection and banking of specimens and data can be very expensive and will 
require support from research funding sources.
1. Prospective multicenter studies with collection and banking of samples with an 
accompanying patient data link, in a manner that complies with regulations for 
disclosure of protected health information of the country in which the trial is being 
performed. Assessors will require adequate training to collect the clinical data 
correctly. The chronic GVHD-focused clinical variables of interest are outlined in 
the companion NIH Consensus Development Project on Criteria for Clinical Trials 
in Chronic GVHD Working Group reports. Table 4 presents the minimal 
recommended data elements that should be linked with each stored sample.
2. Sample acquisition protocols should incorporate both calendar-driven time points 
and event-driven sample collection. Examples of event-driven sample collection 
include the point when the patient is first diagnosed with chronic GVHD (or within 
2 months) or before start of systemic treatment or at the time of change in 
treatment. Thus, in the presence of chronic GVHD, we recommend that samples 
should be obtained within 2 months of onset or treatment change. Since the 
immune environment changes with post-transplant immune reconstitution, time-
matched samples should also be obtained from patients who do not have chronic 
GVHD to serve as controls. In the absence of chronic GVHD, we recommend that 
samples should be obtained at 3, 6, and 12 months, with additional sampling 
considered at 9 months, and 18–24 months after transplantation. Ideally, additional 
samples should be collected yearly, if possible for 6–8 years especially if studies on 
long term changes associated with established cGVHD are being considered. This 
schedule will adequately provide samples during the period of greatest risk for 
development of chronic GVHD and will also allow long-term studies after chronic 
GVHD treatment.
3. A centralized repository at the National Marrow Donor Program (NMDP) or 
possibly a virtual repository with multiple sites collecting in a standardized manner 
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should be established. In the BMT CTN 1201 trial on acute GVHD, shipping of 
blood up to day +100 has provided materials for processing in a central site. 
Collection directly into EDTA, Cytochex and Paxgene tubes has provided material 
for studies of plasma antibodies and stable cytokines, flow cytometric phenotyping 
of lymphocytes and preservation of RNA for molecular analyses. This powerful 
approach avoids the need to have specialized local facilities for processing and 
preservation and standardizes processing and assays to ensure consistent results 
[26–28]. However, this approach is limited in three ways. First, plasma cytokines 
and chemokines are sensitive to both the choice of anticoagulant and the time 
interval from collection to processing and storage [27, 29]. At individual sites with 
dedicated core facilities, rapid separation and freezing of serum and plasma (both 
heparin and EDTA) are recommended for better preservation of cytokines and 
chemokines. Storing multiple small aliquots (0.5 – 1 mL/vial for plasma/serum and 
2 × 106 for phenotyping studies and 5 × 106 cells for functional studies per vial 
with ideally 5 vials for each patient and time point) avoids refreezing. The volume 
of blood or tissue collected must be compliant with IRB maximum criteria. 
Unusual methods to obtain cells, such as leukapheresis, must be considered 
carefully regarding the risks to the subject. Collection in multiple anticoagulants is 
preferred, since anticoagulant choice affects measured ELISA cytokine levels and 
may limit metabolome recovery [27, 30–32]. Second, storing blood cells for later 
analysis – particularly in numbers adequate for flow cytometry (at least 5 × 106 
cells) has the advantage of preserving valuable patient materials for flow 
cytometric, molecular and functional assays using rapidly developing new 
technologies. Finally, the calendar-driven sample approach is inflexible in timing 
and limited in scope of tissues examined. Collection of event-driven samples, such 
as on the day of diagnosis or of new organ involvement, may be critical to 
identifying transient biomarkers. Chronic GVHD is pleomorphic; biopsies of 
chronic GVHD target organs (skin, intestine, liver, and mucosa) or collection of 
local biofluids such as saliva or bronchial lavage fluid, can be more informative 
about infiltrating cells and local chemokines than systemic measurements of blood. 
Formalin-fixed, paraffin embedded diagnostic biopsies of chronic GVHD-affected 
tissues can be analyzed in more detail with multiparameter immunohistochemistry 
or serve as a source of securely preserved RNA and microRNA for multiplex RNA 
analyses [33, 34]. Even if resources to collect these sample types are not available 
at all sites, dedicated large cores/clinical centers should continue to collect and 
bank these quality samples locally or with the intent to ship cryopreserved 
materials to centralized repositories, as in the Chronic GVHD Consortium trials.
4. Subject permission to use banked samples in future research investigations and to 
exchange materials with other institutions should be incorporated into the informed 
consent documents. The use of new tools for genome sequencing raises ethical 
concerns relating to incidental findings and highlight the need for proper 
development of consent documents [35]. Genetic studies have the potential to 
identify incidental findings of potential health or reproductive importance that are 
outside the aims of the study but may have actionable results [36]. A recent study 
of exome sequencing suggested such actionable results might be found in 1% of 
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participants [37]. In the case of transplant recipients, incidental findings from 
testing blood cells could be relevant to the donor and their close relatives. A model 
template for consents for studies involving genomic sequencing has been 
developed at the NCI/CCR clinical research operations website (https://
ccrod.cancer.gov/confluence/display/CCRCRO/Templates) to address these issues 
for patients and donors.
CANDIDATE BIOMARKERS IN CHRONIC GVHD
Potential chronic GVHD biomarkers have been evaluated in both hypothesis-driven and 
discovery-based testing for specific clinical applications. The data have come primarily from 
single centers or from a number of collaborating centers; in most cases, the findings have 
not been assessed as part of large multicenter trials. Despite promising prior investigation, 
few potential biomarkers have been verified in independent large cohorts of patients as 
recommended by this consensus document [38]. In Table 5 we present published candidate 
chronic GVHD biomarkers, organized by application (diagnostic, prognostic, risk 
stratification, predictive), and then in ascending strata based on the strength of the published 
evidence. This table illustrates how very few biomarkers have been identified from studies 
incorporating discovery and independent verification. In addition, studies of chronic GVHD 
therapeutic response are lacking. Among potential biomarker applications, we emphasize 
prognostic, risk stratification and predictive biomarkers as major priorities for future 
investigation. As a reminder, biomarkers are observational correlations and might not 
necessarily reflect the underlying chronic GVHD pathology. However, they often do, and 
the biology of the markers listed in Table 5 will be discussed elsewhere.
In conclusion, although progress has been made, much work will be required to verify and 
qualify the candidate biomarkers identified in previous studies, and to implement high-
throughput methods with appropriately collected specimens for future discovery-based 
approaches. Close coordination between multi-specialty clinical and laboratory-based 
groups, as well as regulatory agencies and industry partners, will be needed to pursue such 
studies successfully. We are confident that identification, verification and qualification of 
biomarkers will greatly assist the development and evaluation of new approaches for 
treating chronic GVHD.
Acknowledgments
This project was supported by the National Institutes of Health’s (NIH’s) National Cancer Institute, Center for 
Cancer Research, Intramural Research Program and Division of Cancer Treatment and Diagnosis, Cancer Therapy 
Evaluation Program; Office of Rare Disease Research, National Center for Advancing Translational Sciences; 
Division of Allergy, Immunology and Transplantation, National Institute of Allergy and Infectious Diseases; 
National Heart Lung and Blood Institute, Division of Blood Diseases and Resources. The authors want to 
acknowledge the following individuals and organizations that, by their participation, made this project possible: 
American Society for Blood and Marrow Transplantation, Center for International Bone and Marrow Transplant 
Research, US Chronic GVHD Consortium (supported by ORDR/NCATS and NCI), German-Austrian-Swiss 
chronic GVHD Consortium, National Marrow Donor Program, the Health Resources and Services Administration, 
Division of Transplantation, US Department of Human Health and Services, Canadian Blood and Marrow 
Transplant Group, European Group for Blood and Marrow Transplantation, Pediatric Blood and Marrow Transplant 
Consortium, and the representatives of the Brazilian Chronic GVHD consortium (Drs. Maria Claudia Moreira, 
Márcia de Matos Silva and Vaneuza Funke) and Deutsche José Carreras Leukämie-Stiftung. The authors would like 
to thank Dr. Joseph Antin (Dana Farber Cancer Center, Boston, MA, USA), Dr. Hildegard Greinix (Medical 
University of Vienna, Vienna, Austria), and Dr. Gerard Socie (University Paris VII & AP-HP, Hospital Saint Louis, 
Paczesny et al. Page 11
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2015 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Paris, France) for their critical review of the manuscript. The organizers are in debt to patients and patient and 
research advocacy groups, who made this process much more meaningful by their engagement. Acknowledgement 
goes to the Meredith Cowden GVHD foundation for facilitating the initial planning meeting in Cleveland in 
November of 2013 in conjunction with the National GVHD Symposium. The project group also recognizes the 
contributions of numerous colleagues in the field of blood and marrow transplantation in the US and 
internationally, medical specialists and consultants, the pharmaceutical industry, and the NIH and US Food and 
Drug Administration professional staff for their intellectual input, dedication, and enthusiasm on the road to 
completion of these documents. For their expert contributions to this 2014 NIH Biomarkers Consensus Working 
Group document special acknowledgements to Ms. Licia Masuch, Ms. Kristie Bradley, and Ms. Linda Henson for 
assistance in the manuscript preparation. The opinions expressed are those of the authors and do not represent the 
position of the National Cancer Institute, the National Heart, Lung and Blood Institute, the National Institute of 
Allergy and Infectious Diseases, the National Institutes of Health, the Food and Drug Administration, or the United 
States Government.
References
1. Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, et al. Long-term 
survival and late deaths after allogeneic hematopoietic cell transplantation. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology. 2011; 29:2230–9. 
[PubMed: 21464398] 
2. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, et al. National Institutes of 
Health consensus development project on criteria for clinical trials in chronic graft-versus-host 
disease: I. Diagnosis and staging working group report. Biology of blood and marrow 
transplantation : journal of the American Society for Blood and Marrow Transplantation. 2005; 
11:945–56.
3. Inamoto Y, Jagasia M, Wood WA, Pidala J, Palmer J, Khera N, et al. Investigator feedback about 
the 2005 NIH diagnostic and scoring criteria for chronic GVHD. Bone marrow transplantation. 
2014; 49:532–8. [PubMed: 24464142] 
4. Schultz KR, Miklos DB, Fowler D, Cooke K, Shizuru J, Zorn E, et al. Toward biomarkers for 
chronic graft-versus-host disease: National Institutes of Health consensus development project on 
criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group 
Report. Biol Blood Marrow Transpl. 2006; 12:126–37.
5. Biomarkers Definitions Working G. Biomarkers and surrogate endpoints: preferred definitions and 
conceptual framework. Clinical pharmacology and therapeutics. 2001; 69:89–95. [PubMed: 
11240971] 
6. Perspectives on Biomarker and Surrogate Endpoint Evaluation:Discussion Forum Summary. The 
National Academies Press; Washington, DC: 2011. 
7. Khleif SN, Doroshow JH, Hait WN. Collaborative A-F-NCB. AACR-FDA-NCI Cancer Biomarkers 
Collaborative consensus report: advancing the use of biomarkers in cancer drug development. 
Clinical cancer research : an official journal of the American Association for Cancer Research. 
2010; 16:3299–318. [PubMed: 20501613] 
8. Polley MY, Freidlin B, Korn EL, Conley BA, Abrams JS, McShane LM. Statistical and practical 
considerations for clinical evaluation of predictive biomarkers. Journal of the National Cancer 
Institute. 2013; 105:1677–83. [PubMed: 24136891] 
9. Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, et al. Post-transplant T cell 
chimerism predicts graft versus host disease but not disease relapse in patients undergoing an 
alemtuzumab based reduced intensity conditioned allogeneic transplant. Leukemia research. 2013; 
37:561–5. [PubMed: 23395505] 
10. Elkaim E, Picard C, Galambrun C, Barlogis V, Loundou A, Curtillet C, et al. Peripheral blood cells 
chimerism after unrelated cord blood transplantation in children: kinetics, predictive factors and 
impact on post-transplant outcome. British journal of haematology. 2014; 166:557–65. [PubMed: 
24779895] 
11. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Biomarker 
Qualification Program. Web. Jan. 2014 http://www.fda.gov/Drugs/DevelopmentApprovalProcess/
DrugDevelopmentToolsQualificationProgram/ucm284076.htm
12. Ransohoff DF. Rules of evidence for cancer molecular-marker discovery and validation. Nature 
reviews Cancer. 2004; 4:309–14.
Paczesny et al. Page 12
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2015 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
13. Ransohoff DF, Gourlay ML. Sources of bias in specimens for research about molecular markers 
for cancer. Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology. 2010; 28:698–704. [PubMed: 20038718] 
14. Pepe, MS. The Statistical Evaluation of Medical Tests for Classification and Prediction. New 
York: Oxford University Press; 2003. 
15. Altelaar AF, Munoz J, Heck AJ. Next-generation proteomics: towards an integrative view of 
proteome dynamics. Nature reviews Genetics. 2013; 14:35–48.
16. Patti GJ, Yanes O, Siuzdak G. Innovation: Metabolomics: the apogee of the omics trilogy. Nature 
reviews Molecular cell biology. 2012; 13:263–9.
17. Kitko CL, Levine JE, Storer BE, Chai X, Fox DA, Braun TM, et al. Plasma CXCL9 elevations 
correlate with chronic GVHD diagnosis. Blood. 2014; 123:786–93. [PubMed: 24363401] 
18. Cohen IR. Autoantibody repertoires, natural biomarkers, and system controllers. Trends in 
immunology. 2013; 34:620–5. [PubMed: 23768955] 
19. Newell EW, Davis MM. Beyond model antigens: high-dimensional methods for the analysis of 
antigen-specific T cells. Nature biotechnology. 2014; 32:149–57.
20. Imanguli MM, Swaim WD, League SC, Gress RE, Pavletic SZ, Hakim FT. Increased T-bet+ 
cytotoxic effectors and type I interferon-mediated processes in chronic graft-versus-host disease of 
the oral mucosa. Blood. 2009; 113:3620–30. [PubMed: 19168793] 
21. Espina V, Wulfkuhle JD, Calvert VS, VanMeter A, Zhou W, Coukos G, et al. Laser-capture 
microdissection. Nature protocols. 2006; 1:586–603.
22. Chaussabel D, Pascual V, Banchereau J. Assessing the human immune system through blood 
transcriptomics. BMC biology. 2010; 8:84. [PubMed: 20619006] 
23. Pritchard CC, Cheng HH, Tewari M. MicroRNA profiling: approaches and considerations. Nature 
reviews Genetics. 2012; 13:358–69.
24. Absher DM, Li X, Waite LL, Gibson A, Roberts K, Edberg J, et al. Genome-wide DNA 
methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of 
interferon genes and compositional changes to CD4+ T-cell populations. PLoS genetics. 2013; 
9:e1003678. [PubMed: 23950730] 
25. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, et al. Direct multiplexed 
measurement of gene expression with color-coded probe pairs. Nature biotechnology. 2008; 
26:317–25.
26. Asare AL, Kolchinsky SA, Gao Z, Wang R, Raddassi K, Bourcier K, et al. Differential gene 
expression profiles are dependent upon method of peripheral blood collection and RNA isolation. 
BMC genomics. 2008; 9:474. [PubMed: 18847473] 
27. Biancotto A, Feng X, Langweiler M, Young NS, McCoy JP. Effect of anticoagulants on 
multiplexed measurement of cytokine/chemokines in healthy subjects. Cytokine. 2012; 60:438–46. 
[PubMed: 22705152] 
28. Maecker HT, McCoy JP, Nussenblatt R. Standardizing immunophenotyping for the Human 
Immunology Project. Nature reviews Immunology. 2012; 12:191–200.
29. Biancotto A, Wank A, Perl S, Cook W, Olnes MJ, Dagur PK, et al. Baseline levels and temporal 
stability of 27 multiplexed serum cytokine concentrations in healthy subjects. PloS one. 2013; 
8:e76091. [PubMed: 24348989] 
30. Guide MSP. http://www.metabolon.com/media/130315/Metabolon-Sample-Prep-Guidelines.pdf
31. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, et al. Procedures 
for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid 
chromatography coupled to mass spectrometry. Nature protocols. 2011; 6:1060–83.
32. Patil R, Shukre S, Paranjape R, Thakar M. Heparin and EDTA anticoagulants differentially affect 
the plasma cytokine levels in humans. Scandinavian journal of clinical and laboratory 
investigation. 2013; 73:452–5. [PubMed: 23772882] 
33. Scott DW, Wright GW, Williams PM, Lih CJ, Walsh W, Jaffe ES, et al. Determining cell-of-origin 
subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-
embedded tissue. Blood. 2014; 123:1214–7. [PubMed: 24398326] 
34. Culpin RE, Sieniawski M, Proctor SJ, Menon G, Mainou-Fowler T. MicroRNAs are suitable for 
assessment as biomarkers from formalin-fixed paraffin-embedded tissue, and miR-24 represents 
Paczesny et al. Page 13
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2015 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
an appropriate reference microRNA for diffuse large B-cell lymphoma studies. Journal of clinical 
pathology. 2013; 66:249–52. [PubMed: 23172553] 
35. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, et al. ACMG recommendations 
for reporting of incidental findings in clinical exome and genome sequencing. Genetics in 
medicine : official journal of the American College of Medical Genetics. 2013; 15:565–74. 
[PubMed: 23788249] 
36. Wolf SM, Lawrenz FP, Nelson CA, Kahn JP, Cho MK, Clayton EW, et al. Managing incidental 
findings in human subjects research: analysis and recommendations. The Journal of law, medicine 
& ethics : a journal of the American Society of Law, Medicine & Ethics. 2008; 36:219–48. 1.
37. Dorschner MO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego CJ, et al. 
Actionable, pathogenic incidental findings in 1,000 participants’ exomes. American journal of 
human genetics. 2013; 93:631–40. [PubMed: 24055113] 
38. Pidala J, Sarwal M, Roedder S, Lee SJ. Biologic markers of chronic GVHD. Bone marrow 
transplantation. 2014; 49:324–31. [PubMed: 23872737] 
39. Abrahamsen IW, Somme S, Heldal D, Egeland T, Kvale D, Tjonnfjord GE. Immune reconstitution 
after allogeneic stem cell transplantation: the impact of stem cell source and graft-versus-host 
disease. Haematologica. 2005; 90:86–93. [PubMed: 15642674] 
40. D’Orsogna LJ, Wright MP, Krueger RG, McKinnon EJ, Buffery SI, Witt CS, et al. Allogeneic 
hematopoietic stem cell transplantation recipients have defects of both switched and igm memory 
B cells. Biology of blood and marrow transplantation : journal of the American Society for Blood 
and Marrow Transplantation. 2009; 15:795–803.
41. Greinix HT, Pohlreich D, Kouba M, Kormoczi U, Lohmann I, Feldmann K, et al. Elevated 
numbers of immature/transitional CD21- B lymphocytes and deficiency of memory CD27+ B cells 
identify patients with active chronic graft-versus-host disease. Biology of blood and marrow 
transplantation : journal of the American Society for Blood and Marrow Transplantation. 2008; 
14:208–19.
42. Kuzmina Z, Greinix HT, Weigl R, Kormoczi U, Rottal A, Frantal S, et al. Significant differences 
in B-cell subpopulations characterize patients with chronic graft-versus-host disease-associated 
dysgammaglobulinemia. Blood. 2011; 117:2265–74. [PubMed: 21063025] 
43. Sarantopoulos S, Stevenson KE, Kim HT, Cutler CS, Bhuiya NS, Schowalter M, et al. Altered B-
cell homeostasis and excess BAFF in human chronic graft-versus-host disease. Blood. 2009; 
113:3865–74. [PubMed: 19168788] 
44. She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z, et al. Altered Toll-like receptor 9 
responses in circulating B cells at the onset of extensive chronic graft-versus-host disease. Biol 
Blood Marrow Transpl. 2007; 13:386–97.
45. Miura Y, Thoburn CJ, Bright EC, Phelps ML, Shin T, Matsui EC, et al. Association of Foxp3 
regulatory gene expression with graft-versus-host disease. Blood. 2004; 104:2187–93. [PubMed: 
15172973] 
46. Zorn E, Kim HT, Lee SJ, Floyd BH, Litsa D, Arumugarajah S, et al. Reduced frequency of 
FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease. Blood. 
2005; 106:2903–11. [PubMed: 15972448] 
47. Matsuoka K, Kim HT, McDonough S, Bascug G, Warshauer B, Koreth J, et al. Altered regulatory 
T cell homeostasis in patients with CD4+ lymphopenia following allogeneic hematopoietic stem 
cell transplantation. The Journal of clinical investigation. 2010; 120:1479–93. [PubMed: 
20389017] 
48. Rozmus J, Schultz KR, Wynne K, Kariminia A, Satyanarayana P, Krailo M, et al. Early and late 
extensive chronic graft-versus-host disease in children is characterized by different Th1/Th2 
cytokine profiles: findings of the Children’s Oncology Group Study ASCT0031. Biology of blood 
and marrow transplantation : journal of the American Society for Blood and Marrow 
Transplantation. 2011; 17:1804–13.
49. Tanaka J, Imamura M, Kasai M, Hashino S, Kobayashi S, Noto S, et al. Th2 cytokines (IL-4, IL-10 
and IL-13) and IL-12 mRNA expression by concanavalin A-stimulated peripheral blood 
mononuclear cells during chronic graft-versus-host disease. European journal of haematology. 
1996; 57:111–3. [PubMed: 8698123] 
Paczesny et al. Page 14
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2015 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
50. Dander E, Balduzzi A, Zappa G, Lucchini G, Perseghin P, Andre V, et al. Interleukin-17-
producing T-helper cells as new potential player mediating graft-versus-host disease in patients 
undergoing allogeneic stem-cell transplantation. Transplantation. 2009; 88:1261–72. [PubMed: 
19996925] 
51. Barak V, Levi-Schaffer F, Nisman B, Nagler A. Cytokine dysregulation in chronic graft versus 
host disease. Leukemia Lymphoma. 1995; 17:169–73. [PubMed: 7773155] 
52. Li Q, Zhai Z, Xu X, Shen Y, Zhang A, Sun Z, et al. Decrease of CD4(+)CD25(+) regulatory T 
cells and TGF-beta at early immune reconstitution is associated to the onset and severity of graft-
versus-host disease following allogeneic haematogenesis stem cell transplantation. Leukemia 
research. 2010; 34:1158–68. [PubMed: 20409584] 
53. Skert C, Damiani D, Michelutti A, Patriarca F, Arpinati M, Fil C, et al. Kinetics of Th1/Th2 
cytokines and lymphocyte subsets to predict chronic GVHD after allo-SCT: results of a 
prospective study. Bone marrow transplantation. 2009; 44:729–37. [PubMed: 19398965] 
54. Ritchie D, Seconi J, Wood C, Walton J, Watt V. Prospective monitoring of tumor necrosis factor 
alpha and interferon gamma to predict the onset of acute and chronic graft-versus-host disease 
after allogeneic stem cell transplantation. Biol Blood Marrow Tr. 2005; 11:706–12.
55. Kim DH, Lee NY, Sohn SK, Baek JH, Kim JG, Suh JS, et al. IL-10 promoter gene polymorphism 
associated with the occurrence of chronic GVHD and its clinical course during systemic 
immunosuppressive treatment for chronic GVHD after allogeneic peripheral blood stem cell 
transplantation. Transplantation. 2005; 79:1615–22. [PubMed: 15940053] 
56. Mullighan C, Heatley S, Doherty K, Szabo F, Grigg A, Hughes T, et al. Non-HLA immunogenetic 
polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell 
transplantation. Transplantation. 2004; 77:587–96. [PubMed: 15084940] 
57. Rocha V, Franco RF, Porcher R, Bittencourt H, Silva WA Jr, Latouche A, et al. Host defense and 
inflammatory gene polymorphisms are associated with outcomes after HLA-identical sibling bone 
marrow transplantation. Blood. 2002; 100:3908–18. [PubMed: 12393699] 
58. Sivula J, Turpeinen H, Volin L, Partanen J. Association of IL-10 and IL-10Rbeta gene 
polymorphisms with graft-versus-host disease after haematopoietic stem cell transplantation from 
an HLA-identical sibling donor. BMC Immunol. 2009; 10:24. [PubMed: 19409109] 
59. Takahashi H, Furukawa T, Hashimoto S, Suzuki N, Kuroha T, Yamazaki F, et al. Contribution of 
TNF-alpha and IL-10 gene polymorphisms to graft-versus-host disease following allo-
hematopoietic stem cell transplantation. Bone marrow transplantation. 2000; 26:1317–23. 
[PubMed: 11223972] 
60. Cavet J, Dickinson AM, Norden J, Taylor PR, Jackson GH, Middleton PG. Interferon-gamma and 
interleukin-6 gene polymorphisms associate with graft-versus-host disease in HLA-matched 
sibling bone marrow transplantation. Blood. 2001; 98:1594–600. [PubMed: 11520812] 
61. Cullup H, Dickinson AM, Cavet J, Jackson GH, Middleton PG. Polymorphisms of 
interleukin-1alpha constitute independent risk factors for chronic graft-versus-host disease after 
allogeneic bone marrow transplantation. British journal of haematology. 2003; 122:778–87. 
[PubMed: 12930389] 
62. Visentainer JEL, Lieber SR, Persoli LBL, Vigorito AC, Aranha FJP, de Brito Eid KA, et al. Serum 
cytokine levels and acute graft-versus-host disease after HLA-identical hematopoietic stem cell 
transplantation. Experimental hematology. 2003; 31:1044–50. [PubMed: 14585368] 
63. Bertinetto FE, Dall’Omo AM, Mazzola GA, Rendine S, Berrino M, Bertola L, et al. Role of non-
HLA genetic polymorphisms in graft-versus-host disease after haematopoietic stem cell 
transplantation. Int J Immunogenet. 2006; 33:375–84. [PubMed: 16984283] 
64. Viel DO, Tsuneto LT, Sossai CR, Lieber SR, Marques SB, Vigorito AC, et al. IL2 and TNFA gene 
polymorphisms and the risk of graft-versus-host disease after allogeneic haematopoietic stem cell 
transplantation. Scandinavian journal of immunology. 2007; 66:703–10. [PubMed: 18021367] 
65. Zorn E, Mohseni M, Kim H, Porcheray F, Lynch A, Bellucci R, et al. Combined CD4+ donor 
lymphocyte infusion and low-dose recombinant IL-2 expand FOXP3+ regulatory T cells following 
allogeneic hematopoietic stem cell transplantation. Biology of blood and marrow transplantation : 
journal of the American Society for Blood and Marrow Transplantation. 2009; 15:382–8.
Paczesny et al. Page 15
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2015 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
66. Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP 3rd, et al. Interleukin-2 and 
regulatory T cells in graft-versus-host disease. The New England journal of medicine. 2011; 
365:2055–66. [PubMed: 22129252] 
67. Matsuoka K, Koreth J, Kim HT, Bascug G, McDonough S, Kawano Y, et al. Low-dose 
interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-
host disease. Science translational medicine. 2013; 5:179ra43.
68. Mahadeo KM, Masinsin B, Kapoor N, Shah AJ, Abdel-Azim H, Parkman R. Immunologic 
resolution of human chronic graft-versus-host disease. Biology of blood and marrow 
transplantation : journal of the American Society for Blood and Marrow Transplantation. 2014; 
20:1508–15.
69. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A, et al. Biomarkers in newly 
diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children’s 
Oncology Group. Blood. 2008; 111:3276–85. [PubMed: 17925486] 
70. Kobayashi S, Imamura M, Hashino S, Tanaka J, Asaka M. Clinical relevance of serum soluble 
interleukin-2 receptor levels in acute and chronic graft-versus-host disease. Leukemia & 
lymphoma. 1997; 28:159–69. [PubMed: 9498715] 
71. D’Asaro M, Dieli F, Caccamo N, Musso M, Porretto F, Salerno A. Increase of CCR7− CD45RA+ 
CD8 T cells (T(EMRA)) in chronic graft-versus-host disease. Leukemia. 2006; 20:545–7. 
[PubMed: 16408100] 
72. Yamashita K, Choi U, Woltz PC, Foster SF, Sneller MC, Hakim FT, et al. Severe chronic graft-
versus-host disease is characterized by a preponderance of CD4(+) effector memory cells relative 
to central memory cells. Blood. 2004; 103:3986–8. [PubMed: 14764530] 
73. Arpinati M, Chirumbolo G, Marzocchi G, Baccarani M, Rondelli D. Increased donor 
CD86+CD14+ cells in the bone marrow and peripheral blood of patients with chronic graft-versus-
host disease. Transplantation. 2008; 85:1826–32. [PubMed: 18580477] 
74. Kohrt HE, Tian L, Li L, Alizadeh AA, Hsieh S, Tibshirani RJ, et al. Identification of gene 
microarray expression profiles in patients with chronic graft-versus-host disease following 
allogeneic hematopoietic cell transplantation. Clin Immunol. 2013; 148:124–35. [PubMed: 
23685278] 
75. Westekemper H, Meller S, Citak S, Schulte C, Steuhl KP, Homey B, et al. Differential chemokine 
expression in chronic GVHD of the conjunctiva. Bone marrow transplantation. 2010; 45:1340–6. 
[PubMed: 20140022] 
76. McGuirk J, Hao G, Hou W, Abhyankar S, Williams C, Yan W, et al. Serum proteomic profiling 
and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell 
transplantation. Journal of hematology & oncology. 2009; 2:17. [PubMed: 19379511] 
77. Liem L, van Houwelingen H, Goulmy E. Serum Cytokine Levels after HLA-identical Bone 
Marrow Transplantation. Transplantation. 1998; 66:863–71. [PubMed: 9798695] 
78. Bassim CW, Ambatipudi KS, Mays JW, Edwards DA, Swatkoski S, Fassil H, et al. Quantitative 
salivary proteomic differences in oral chronic graft-versus-host disease. Journal of clinical 
immunology. 2012; 32:1390–9. [PubMed: 22806177] 
79. Devic I, Shi M, Schubert MM, Lloid M, Izutsu KT, Pan C, et al. Proteomic analysis of saliva from 
patients with oral chronic graft-versus-host disease. Biology of blood and marrow transplantation : 
journal of the American Society for Blood and Marrow Transplantation. 2014; 20:1048–55.
80. Wechalekar A, Cranfield T, Sinclair D, Ganzckowski M. Occurrence of autoantibodies in chronic 
graft vs. host disease after allogeneic stem cell transplantation. Clinical and laboratory 
haematology. 2005; 27:247–9. [PubMed: 16048492] 
81. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S, et al. Stimulatory 
autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. 
Blood. 2007; 110:237–41. [PubMed: 17363728] 
82. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ, et al. Antibody responses to H-Y minor 
histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. 
Blood. 2005; 105:2973–8. [PubMed: 15613541] 
83. Rajasekar R, Mathews V, Lakshmi KM, Sellathamby S, George B, Viswabandya A, et al. 
Plasmacytoid dendritic cell count on day 28 in HLA-matched related allogeneic peripheral blood 
Paczesny et al. Page 16
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2015 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
stem cell transplant predicts the incidence of acute and chronic GVHD. Biology of blood and 
marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 
2008; 14:344–50.
84. Larghero J, Rocha V, Porcher R, Filion A, Ternaux B, Lacassagne MN, et al. Association of bone 
marrow natural killer cell dose with neutrophil recovery and chronic graft-versus-host disease after 
HLA identical sibling bone marrow transplants. British journal of haematology. 2007; 138:101–9. 
[PubMed: 17555453] 
85. Yamasaki S, Henzan H, Ohno Y, Yamanaka T, Iino T, Itou Y, et al. Influence of transplanted dose 
of CD56+ cells on development of graft-versus-host disease in patients receiving G-CSF-
mobilized peripheral blood progenitor cells from HLA-identical sibling donors. Bone marrow 
transplantation. 2003; 32:505–10. [PubMed: 12942097] 
86. Sarantopoulos S, Stevenson KE, Kim HT, Bhuiya NS, Cutler CS, Soiffer RJ, et al. High Levels of 
B-Cell Activating Factor in Patients with Active Chronic Graft-Versus-Host Disease. Clinical 
cancer research : an official journal of the American Association for Cancer Research. 2007; 
13:6107–14. [PubMed: 17947475] 
87. Shimura K, Ashihara E, Shimazaki C, Matsunaga S, Taniguchi K, Uchiyama H, et al. Circulating 
endothelial progenitor cells decreased in patients with sclerodermatous chronic graft-versus-host 
disease. Biology of blood and marrow transplantation : journal of the American Society for Blood 
and Marrow Transplantation. 2008; 14:426–37.
88. Pratt LM, Liu Y, Ugarte-Torres A, Hoegh-Petersen M, Podgorny PJ, Lyon AW, et al. IL15 levels 
on day 7 after hematopoietic cell transplantation predict chronic GVHD. Bone marrow 
transplantation. 2013; 48:722–8. [PubMed: 23165502] 
89. Clark WB, Brown-Gentry KD, Crawford DC, Fan KH, Snavely J, Chen H, et al. Genetic variation 
in recipient B-cell activating factor modulates phenotype of GVHD. Blood. 2011; 118:1140–4. 
[PubMed: 21628416] 
90. Broen K, van der Waart AB, Greupink-Draaisma A, Metzig J, Feuth T, Schaap NP, et al. 
Polymorphisms in CCR6 are associated with chronic graft-versus-host disease and invasive fungal 
disease in matched-related hematopoietic stem cell transplantation. Biology of blood and marrow 
transplantation : journal of the American Society for Blood and Marrow Transplantation. 2011; 
17:1443–9.
91. Inamoto Y, Murata M, Katsumi A, Kuwatsuka Y, Tsujimura A, Ishikawa Y, et al. Donor single 
nucleotide polymorphism in the CCR9 gene affects the incidence of skin GVHD. Bone marrow 
transplantation. 2010; 45:363–9. [PubMed: 19525985] 
92. Shimada M, Onizuka M, Machida S, Suzuki R, Kojima M, Miyamura K, et al. Association of 
autoimmune disease-related gene polymorphisms with chronic graft-versus-host disease. British 
journal of haematology. 2007; 139:458–63. [PubMed: 17868046] 
93. Ostrovsky O, Shimoni A, Rand A, Vlodavsky I, Nagler A. Genetic variations in the heparanase 
gene (HPSE) associate with increased risk of GVHD following allogeneic stem cell 
transplantation: effect of discrepancy between recipients and donors. Blood. 2010; 115:2319–28. 
[PubMed: 20075159] 
94. Kornblit B, Masmas T, Petersen SL, Madsen HO, Heilmann C, Schejbel L, et al. Association of 
HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biology 
of blood and marrow transplantation : journal of the American Society for Blood and Marrow 
Transplantation. 2010; 16:239–52.
95. Bogunia-Kubik K, Mlynarczewska A, Wysoczanska B, Lange A. Recipient interferon-gamma 3/3 
genotype contributes to the development of chronic graft-versus-host disease after allogeneic 
hematopoietic stem cell transplantation. Haematologica. 2005; 90:425–6. [PubMed: 15749687] 
96. Ambruzova Z, Mrazek F, Raida L, Stahelova A, Faber E, Indrak K, et al. Possible impact of 
MADCAM1 gene single nucleotide polymorphisms to the outcome of allogeneic hematopoietic 
stem cell transplantation. Human immunology. 2009; 70:457–60. [PubMed: 19286444] 
97. Boukouaci W, Busson M, Peffault de Latour R, Rocha V, Suberbielle C, Bengoufa D, et al. 
MICA-129 genotype, soluble MICA, and anti-MICA antibodies as biomarkers of chronic graft-
versus-host disease. Blood. 2009; 114:5216–24. [PubMed: 19786616] 
Paczesny et al. Page 17
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2015 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
98. Arora M, Lindgren B, Basu S, Nagaraj S, Gross M, Weisdorf D, et al. Polymorphisms in the base 
excision repair pathway and graft-versus-host disease. Leukemia. 2010; 24:1470–5. [PubMed: 
20574454] 
99. Olivieri A, Cimminiello M, Corradini P, Mordini N, Fedele R, Selleri C, et al. Long-term outcome 
and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-
refractory chronic GVHD. Blood. 2013; 122:4111–8. [PubMed: 24152907] 
APPENDIX: NATIONAL INSTITUTES OF HEALTH CONSENSUS-
DEVELOPMENT PROJECT ON CRITERIA FOR CLINICAL TRIALS IN 
CHRONIC GVHD STEERING COMMITTEE
Members of this committee included: Steven Pavletic, Georgia Vogelsang and Stephanie 
Lee (project chairs), Mary Flowers and Madan Jagasia (Diagnosis and Staging), David 
Kleiner and Howard Shulman (Histopathology), Kirk Schultz and Sophie Paczesny 
(Biomarkers), Stephanie Lee and Steven Pavletic (Response Criteria), Daniel Couriel and 
Paul Carpenter (Ancillary and Supportive Care), Paul Martin and Corey Cutler (Design of 
Clinical Trials), Kenneth Cooke and David Miklos (Chronic GVHD Biology), Roy Wu, 
William Merritt, Linda Griffith, Nancy DiFronzo, Myra Jacobs, Susan Stewart, and 
Meredith Cowden (members).
Paczesny et al. Page 18
Biol Blood Marrow Transplant. Author manuscript; available in PMC 2015 May 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
Example of a predictive biomarker or response biomarker development project
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Table 2
Factors that must be considered for chronic GVHD studies
Factor Impact on chronic GVHD biomarker
Factors affecting biomarkers directly
Tissues involved and NIH chronic 
GVHD score
• Tissues involved
• NIH chronic GVHD score
Immune reconstitution post HCT and 
time from transplant
• Some biomarkers vary with immune reconstitution post-HCT thus time and age 
matched (pediatric vs adult) controls are required.
Concomitant acute GVHD • Concurrent acute GVHD may overlap with classic chronic GVHD manifestations
• Biomarkers may represent late acute GVHD manifestations
Previous acute GVHD and treatment/
prophylaxis of acute GVHD
• The presence of previous acute GVHD and the therapy utilized to treat acute GVHD
• Acute GVHD prophylaxis has the potential for long term impact on immune 
reconstitution (e.g. antibodies such as rituximab, alemtuzumab, and ATG)
Current immune suppression • Many immunosuppressive treatments particularly steroids may affect concentrations 
affect concentration of biomarkers (e.g. sBAFF)
Current infection • Active infections may change cytokine milieu and markers.
• CMV reactivation, pulmonary infections.
Sample processing and storage • Some B cell populations are lost when processed with Ficoll
• Choice of serum or heparin, EDTA or citrate plasma alters analytes
• Processing time after blood draw reduces some analytes
• Collection of the samples may be specific for the type of assay and the type of tissue 
collected (i.e., serum, urine, saliva)
These considerations apply both during the identification and verification of a 
biomarker as well as during its subsequent application.
Covariates and potential confounding factors
Recipient characteristics • Younger age associated with lower incidence of chronic GVHD
• Non-malignant diagnoses may affect the incidence and type of chronic GVHD 
(particularly non-malignant disorders with marrow failure and chromosomal 
instability appear to have a higher rate of chronic GVHD).
• Allo immunized patients may have a lower rate of engraftment resulting in split 
donor chimerism and affecting the incidence of chronic GVHD
• Non-HLA polymorphisms may impact incidence or presentation (i.e., ABO 
incompatibility)
• Biomarkers may be organ specific
Donor characteristics • Unrelated versus related donor
• HLA mismatched versus HLA matched
• Female donor is associated with a higher incidence of chronic GVHD
• UCB, Peripheral, peripheral blood, or marrow graft
• Non-HLA polymorphisms may impact on incidence or presentation (i.e., ABO 
incompatibility)
• Treatment of donor product (i.e., G-CSF, T cell or B cell depletion)
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Factor Impact on chronic GVHD biomarker
Preparative conditioning regimen • MAC versus RIC
• Use of T cell or B cell depletion (TCD, ATG, Campath 1H, Rituximab), all 
associated with a lower incidence of chronic GVHD
• TBI associated with increased cutaneous sclerosis
Footnotes: UCB = umbilical cord blood; TCD = T cell depletion; ATG = Anti-thymocyte antibody; MAC = Myeloablative condition; RIC = 
Reduced Intensity Conditioning
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Table 3
Statistical considerations
A. Analytical performance parameters
• Precision (repeatability and reproducibility of an assay)
• Accuracy
• Assay sensitivity (limit of detection)
• Assay specificity (interference, cross-reactivity)
• Sample type and matrix
• Sample preparation
B. Diagnostic accuracy
• Sensitivity: Proportion of subjects in a sample of patients with the target condition in whom the test is positive.
• Specificity: Proportion of subjects in a sample of patients without the target condition in whom the test is negative.
• Receiver operator characteristic (ROC): A plot of the true-positive rate versus the false-positive rate for all possible thresholds of a 
biomarker.
• Positive predictive value (PPV): Proportion of patients in the overall population with a positive test who have the target condition.
• Negative predictive value (NPV): Proportion of patients in the overall population with a negative test who do not have the target 
condition.
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Table 4
Minimal essential clinical/routine laboratory data to be provided with each sample
Essential data Recommended data (will be marker specific)*
1 Clinical Phenotype
• For diagnosis markers: NIH diagnosis and staging 
forms
• For prediction of response: NIH response to 
treatment forms
• This includes presence or not of concomitant 
features of acute GVHD
Time after transplantation at chronic GVHD 
diagnosis or of time matched non-chronic GVHD 
patients
2 Current type of immunosuppression at the time of time of 
sample collection (if taking corticosteroids: add dose and 
weight of patient)
1) Prior acute GVHD
2) MAC vs. RIC
3) Prior chronic GVHD
4) TCD vs. Not TCD
5) PBSC vs. BM vs. UCB
6) Recent B cell depletion
7) Sex mismatch
8) HLA mismatch
9) Active uncontrolled infection (particularly CMV)
10) Age of the patient and recipient
11) WBC and ALC
Although suggested they are not routinely captured at most centers
12) Prior Immunosuppressive therapies failed
13) Absolute T and B cells counts
14) IgG levels
*Variables that could confound the analyses (Table 2) should be collected in minimal essential data
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en
e 
po
ly
m
or
ph
ism
 a
ss
oc
ia
te
d 
w
ith
 c
hr
on
ic
 G
V
H
D
.
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•
St
re
ng
th
 o
f e
vi
de
nc
e:
 C
at
eg
or
y 
1:
 B
io
m
ar
ke
rs
 su
pp
or
te
d 
by
 g
re
at
er
 q
ua
lit
y 
ev
id
en
ce
, i
nc
lu
di
ng
 c
on
sis
te
nt
 fi
nd
in
gs
 (e
.g.
 ca
nd
ida
te 
bio
ma
rke
r i
s e
lev
ate
d i
n c
hro
nic
 G
VH
D 
pa
tie
nts
 vs
. c
on
tro
ls)
 
ac
ro
ss
 ≥
 2
 st
ud
ie
s, 
irr
es
pe
ct
iv
e 
of
 m
et
ho
do
lo
gy
 u
se
d 
in
 e
ac
h 
re
po
rt,
 o
r (
b) 
ex
am
ine
d i
n 2
 pa
tie
nt 
co
ho
rts
. –
 C
ate
go
ry 
2: 
Stu
die
s h
av
e d
em
on
str
ate
d s
ign
ifi
ca
nt 
fin
din
gs
 in
 a 
sin
gle
 co
ho
rt,
 or
 by
 a 
sin
gl
e 
gr
ou
p.
a
So
m
e 
of
 th
e 
m
ar
ke
rs
 h
av
e 
be
en
 e
va
lu
at
ed
 in
 m
or
e 
th
an
 o
ne
 in
de
pe
nd
en
t p
at
ie
nt
 c
oh
or
t b
y 
ei
th
er
 th
e 
or
ig
in
al
 g
ro
up
s t
o 
id
en
tif
y 
th
e 
m
ar
ke
r o
r b
y 
an
ot
he
r l
ab
or
at
or
y.
 M
or
eo
ve
r s
om
e 
m
ar
ke
rs
 h
av
e 
be
en
 
id
en
tif
ie
d 
by
 d
iff
er
en
t m
et
ho
do
lo
gi
es
 w
he
n 
se
pa
ra
te
 la
bo
ra
to
rie
s h
av
e 
ev
al
ua
te
d 
th
e 
m
ar
ke
r. 
W
e 
ha
ve
 n
ot
 n
ot
ed
 th
es
e 
di
ffe
re
nc
es
 in
 th
is 
ta
bl
e.
b T
hi
s m
ar
ke
r c
ou
ld
 b
e 
co
ns
id
er
ed
 in
 th
e 
ca
te
go
ry
 re
sp
on
se
 to
 th
er
ap
y.
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